Literature DB >> 19366734

A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma.

Natsuo Tomita1, T Kodaira, H Tachibana, T Nakamura, R Nakahara, H Inokuchi, N Mizoguchi, A Takada.   

Abstract

The purpose of this study was to compare radiation treatment plans (RTPs) that used intensity-modulated radiation therapy (IMRT) with helical tomotherapy (HT) or three-dimensional conformal radiation therapy (3D-CRT) for nasal natural killer/T-cell lymphoma (NNKTL). We created RTPs that used IMRT with HT or 3D-CRT for eight NNKTL patients previously treated at our institution and conducted a pilot comparison between the two modalities using the parameters of the target coverage and homogeneity for the planning target volume (PTV) and the maximum and mean doses for organs at risk (OARs). The clinical target volume (CTV) included the gross tumour volume with an additional margin of 1.5 cm and the nasopharynx, palates and nasal cavity; the PTV with the CTV plus a 2 mm margin received a total dose of 50 Gy. IMRT achieved significantly better PTV coverage, with more than 99% of the PTV receiving 90% and 95% of the prescribed dose, whereas 3D-CRT could not provide adequate coverage of the PTV, with 89.1+/-2.6% and 84.5+/-2.7% of the PTV receiving 90% and 95% of the prescribed dose, respectively (both p <0.0001). The homogeneity index was 0.29+/-0.06 for IMRT and 0.046+/-0.022 for 3D-CRT, which was statistically significant (p <0.0001). IMRT tended to provide equivalent or slightly better OAR avoidance than 3D-CRT. In conclusion, 3D-CRT could not provide adequate coverage of the PTV because the PTV was close to many OARs. IMRT should be used for NNKTL because a lack of optimal RTPs could cause local failure.

Entities:  

Mesh:

Year:  2009        PMID: 19366734     DOI: 10.1259/bjr/83758373

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  14 in total

1.  Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties.

Authors:  Youlia M Kirova; Cyrus Chargari
Journal:  World J Radiol       Date:  2011-03-28

2.  Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.

Authors:  Tao Wu; Yong Yang; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Chen Hu; Shu-Nan Qi; Bo Chen; Ye-Xiong Li
Journal:  Blood Adv       Date:  2018-09-25

3.  Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I-II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results.

Authors:  Qianwen Shen; Xuejun Ma; Weigang Hu; Lanfei Chen; Juan Huang; Ye Guo
Journal:  Radiat Oncol       Date:  2013-06-25       Impact factor: 3.481

Review 4.  Image-guided radiation therapy in lymphoma management.

Authors:  Tony Eng; Chul S Ha
Journal:  Radiat Oncol J       Date:  2015-09-30

5.  Assessment and Comparison of Homogeneity and Conformity Indexes in Step-and-Shoot and Compensator-Based Intensity Modulated Radiation Therapy (IMRT) and Three-Dimensional Conformal Radiation Therapy (3D CRT) in Prostate Cancer.

Authors:  Marzieh Salimi; Kaveh Shirani Tak Abi; Hassan Ali Nedaie; Hossein Hassani; Hussain Gharaati; Mahmood Samei; Rezgar Shahi; Hamed Zarei
Journal:  J Med Signals Sens       Date:  2017 Apr-Jun

6.  Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.

Authors:  Claire Wen-Chi Yang; Chun-Wei Wang; Ruey-Long Hong; Chiao-Ling Tsai; Ming Yao; Jih-Luh Tang; Chung-Wu Lin; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  J Radiat Res       Date:  2016-08-16       Impact factor: 2.724

7.  Dosimetric comparison of helical tomotherapy, VMAT, fixed-field IMRT and 3D-conformal radiotherapy for stage I-II nasal natural killer T-cell lymphoma.

Authors:  Xianfeng Liu; Erliang Huang; Ying Wang; Yanan He; Huanli Luo; Mingsong Zhong; Da Qiu; Chao Li; Han Yang; Guanglei He; Juan Zhou; Fu Jin
Journal:  Radiat Oncol       Date:  2017-04-27       Impact factor: 3.481

8.  Intensity-modulated radiotherapy has superior outcomes to three-dimensional conformal radiotherapy in patients with stage IE-IIE extranodal nasal-type natural killer/T-cell lymphoma.

Authors:  Yi-Yang Li; Hai-Qun Lin; Lu-Lu Zhang; Ling-Ling Feng; Shao-Qing Niu; Han-Yu Wang; Yu-Jing Zhang; Xi-Cheng Wang
Journal:  Oncotarget       Date:  2017-03-11

9.  Tomotherapy - a different way of dose delivery in radiotherapy.

Authors:  Tomasz Piotrowski; Małgorzata Skórska; Agata Jodda; Adam Ryczkowski; Joanna Kaźmierska; Krystyna Adamska; Aldona Karczewska-Dzionk; Małgorzata Zmijewska-Tomczak; Hanna Włodarczyk
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

10.  Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage IE /IIE extranodal natural killer/T-cell lymphoma.

Authors:  Han-Yu Wang; Shao-Qing Niu; Yun-Ying Yang; Yi-Yang Li; Hong-Bo Chen; Yu-Jing Zhang
Journal:  Cancer Med       Date:  2018-11-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.